Ansell's Malaysian glove facility awaits FDA reinspection to confirm GMP compliance.
This article was originally published in The Gray Sheet
Executive Summary
ANSELL'S MALAYSIAN GLOVE FACILITY AWAITING FDA REINSPECTION following the company's steps to correct good manufacturing practices deficiencies identified by FDA. Ansell-Perry, which owns the facility and is a subsidiary of Ansell Healthcare, says it is working with the agency to set a date for reinspection, which is needed to confirm the facility's GMP compliance. The facility's latex surgical and exam gloves have been on import detention since November 3, 1995 due to GMP violations.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.